Drug Profile
Research programme: alpha fetoprotein targeting antibody-drug conjugates - Alpha Cancer Technologies/PolyTherics
Alternative Names: ACT 902Latest Information Update: 21 Sep 2021
Price :
$50
*
At a glance
- Originator Alpha Cancer Technologies; PolyTherics
- Class Antineoplastics; Drug conjugates; Lactones; Maytansinoids; Recombinant proteins; Sesquiterpenes
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alveolar soft part sarcoma; Solid tumours